699 related articles for article (PubMed ID: 31253180)
41. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH
Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
43. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
[TBL] [Abstract][Full Text] [Related]
44. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
45. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
46. How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Steinhilber D; Marschalek R
Biochem Pharmacol; 2018 Jan; 147():183-190. PubMed ID: 28943239
[TBL] [Abstract][Full Text] [Related]
47. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
48. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
49. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
50. Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system.
Yokoyama A
Cancer Sci; 2021 Oct; 112(10):3935-3944. PubMed ID: 34251718
[TBL] [Abstract][Full Text] [Related]
51. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
53. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
54. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
55. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
56. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Grey W; Ivey A; Milne TA; Haferlach T; Grimwade D; Uhlmann F; Voisset E; Yu V
Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):105-116. PubMed ID: 28939057
[TBL] [Abstract][Full Text] [Related]
57. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
58. Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model.
Fu JF; Yen TH; Huang YJ; Shih LY
Neoplasia; 2019 May; 21(5):469-481. PubMed ID: 30974389
[TBL] [Abstract][Full Text] [Related]
59. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
60. Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia.
Janssens DH; Meers MP; Wu SJ; Babaeva E; Meshinchi S; Sarthy JF; Ahmad K; Henikoff S
Nat Genet; 2021 Nov; 53(11):1586-1596. PubMed ID: 34663924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]